Alkermes Plc (ALKS)

33.96
NASDAQ : Health Technology
Prev Close 34.94
Day Low/High 33.79 / 34.81
52 Wk Low/High 27.54 / 61.21
Avg Volume 825.40K
Exchange NASDAQ
Shares Outstanding 156.04M
Market Cap 5.45B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alkermes Initiates Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors

Alkermes Initiates Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors

-- Once-Weekly and Once-Every-Three-Week Dosing of ALKS 4230 to be Evaluated as Monotherapy and in Combination With Pembrolizumab --

Alkermes To Present At The 8th Annual SVB Leerink Global Healthcare Conference

Alkermes To Present At The 8th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Feb. 20, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference on Wednesday, Feb.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ALKS, AUY, BY, CCS, CXO, DVN, HGV, IESC, KRG, OMF, VRNT Downgrades: ARR, CTG, JAZZ, PTN, ROX Initiations: LBRT, NINE Read on to get TheStreet Quant Ratings' detailed report:

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models --

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2018 And Provides Financial Expectations For 2019

Alkermes Plc Reports Financial Results For The Year Ended Dec. 31, 2018 And Provides Financial Expectations For 2019

-- Record Revenues of $1.09 Billion in 2018, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales --

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Deadline Reminder: The Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Alkermes Plc, Inc. (ALKS)

Law Offices of Howard G. Smith reminds investors of the February 25, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Alkermes plc, Inc.

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2018 Financial Results

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2018 Financial Results

DUBLIN, Feb. 7, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.

Alkermes Receives Complete Response Letter From U.S. Food And Drug Administration For ALKS 5461 New Drug Application

Alkermes Receives Complete Response Letter From U.S. Food And Drug Administration For ALKS 5461 New Drug Application

DUBLIN, Feb. 1, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors With $100K In Losses Of Important February 25th Deadline - ALKS

ALKS ALERT: Rosen Law Firm Files First Securities Class Action Lawsuit Against Alkermes Public Limited Company; Reminds Investors With $100K In Losses Of Important February 25th Deadline - ALKS

NEW YORK, Jan. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ: ALKS) from February 17, 2017...

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has...

Alkermes Announces Recipients Of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Alkermes Announces Recipients Of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

- 2018 Competitive Grants Program Awards Approximately $400,000 for Research Projects Focused on Substance Use Disorders -

SHAREHOLDER ALERT: Berger Montague Announces Investigation Of Alkermes, Plc (NASDAQ: ALKS) (CUSIP: G01767105)

SHAREHOLDER ALERT: Berger Montague Announces Investigation Of Alkermes, Plc (NASDAQ: ALKS) (CUSIP: G01767105)

PHILADELPHIA, Jan. 10, 2019 /PRNewswire/ -- Berger Montague announced today that Alkermes (NASDAQ: ALKS) and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alkermes Plc - ALKS

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Alkermes Plc - ALKS

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alkermes plc ("Alkermes" or the "Company") (NASDAQ:  ALKS).

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes Plc

Investor Alert: Kaplan Fox Announces Investigation Of Alkermes Plc

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alkermes Plc To Contact The Firm

NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS).

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Alkermes Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alkermes plc ("Alkermes" or "the Company") (NASDAQ: ALKS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...

Alkermes' Corporate Presentation To Be Webcast At The 37th Annual J.P. Morgan Healthcare Conference

Alkermes' Corporate Presentation To Be Webcast At The 37th Annual J.P. Morgan Healthcare Conference

DUBLIN, Jan. 2, 2019 /PRNewswire/ --  Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 37 th Annual J.

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes Plc - ALKS

Alkermes Class Action Lawsuit: Bernstein Liebhard LLP Announces That A Securities Class Action Lawsuit Has Been Filed Against Alkermes Plc - ALKS

NEW YORK, Dec. 28, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alkermes...

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Alkermes Public Limited Company - ALKS

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Alkermes Public Limited Company (NASDAQ:ALKS) from February 17, 2017 through November 1, 2018, inclusive (the...

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

Alkermes Larger Than S&P 500 Component Goodyear Tire & Rubber

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alkermes plc was identified as having a larger market cap than the smaller end of the S&P 500, for example Goodyear Tire & Rubber Co. , according to The Online Investor.

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study Of ALKS 3831 In Patients With Schizophrenia

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study Of ALKS 3831 In Patients With Schizophrenia

-- ALKS 3831 Met Both Co-Primary Endpoints, Demonstrating a Favorable Weight Profile Compared to Olanzapine --

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Alkermes Plc - ALKS

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc.

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes Plc - ALKS

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes Plc - ALKS

NEW YORK, Nov. 9, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS)...

TheStreet Quant Rating: C- (Hold)